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1 The Institute – An Overview  
The Ludwig Boltzmann Institute for Health Technology Assessment (LBI-
HTA) was formally founded on March 1st 2006, and is intended to operate 
for a period of 7 years. Having rented office space in the center of Vienna 
and set up basic infrastructure, the institute started its operational activity 
in May 2006. An evaluation will take place after 4 years of operational activ-
ity in 2010.   
1.1 Budget 
The Ludwig Boltzmann Institute for Health Technology Assessment has a 
budget of 3,2 Mio Euro from 2006 to 2013, which is about 800.000.- Euro p.a. 
The annual budget is funded by the partner-institutions and the Ludwig 
Boltzmann Society.  
Additional third party funding has been acquired through participation in 
the EU-project EUnetHTA (2006-2008), InnoHTA (2008-2009) and through 
two projects with the Austrian federal ministry for health, family and youth 
(HPV vaccination and tissue banks). 
1.2 Partners 
In line with the research policy of the Ludwig Boltzmann Society, the insti-
tute focusses on translational research. According to the research pro-
gramme, strong emphasis is put on applicable short term or medium term 
results. By setting up partnerships between research-producing and re-
search-applying organisations or institutions for the constitution and financ-
ing of the new institute, the transfer of the research results is guaranteed.  
Partner-institutions in the Ludwig Boltzmann Institute for Health Technol-
ogy Assessment are actors in health care administration, owners of public 
hospitals and private universities.   
TILAK/Tiroler Landeskrankenanstalten GmbH 
Anichstraße 35, 6020 Innsbruck 
http://www.tilak.at/ 
KAGES/Steiermärkische Krankenanstalten-GmbH 
Stiftingtalstraße 4-6, 8010 Graz 
http://www.kages.at/ 
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total budget  
of LBI- HTA 
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institutional partners 
 
translational research: 
partners apply results 
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AUVA/Allgemeine Unfallversicherungsanstalt 
Adalbert-Stifterstraße 65, 1201 Wien  
http://www.auva.at/ 
BMGFJ/Bundesministerium für Gesundheit, Familie und Jugend 
Radetzkystraße 2 , 1030 Wien  
http://www.bmgfj.gv.at 
UMIT/Private Universität für Gesundheitswissenschaften, Medizi-
nische Informatik und Technik 
Institut für Public Health, Medical Decision Making und HTA 
Eduard Wallnöfer-Zentrum I, 6060 Hall  
http://www.umit.at/ 
PMU/Paracelsus Medizinische Privatuniversität 
Institut für Public Health  
Ignaz Harrer Straße 79, 5020 Salzburg 
http://www.pmu.ac.at/ 
A cooperational contract has been negotiated with the Austrian Federation 
of Social and Health Insurances and will be effective from 2008 until 2013. 
 
new partner in 2008: 
Federation of 
Health Insurances 
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1.3 Committees 
The LBI-HTA is supported by two committees, namely the Board of Trus-
tees and the Scientific Advisory Group:  
Table 1.3-1: Organigram 
Whereas the research programme for the LBI-HTA provides a general me-
thodical backdrop, agenda setting for the current projects is the task of the 
board of trustees. The board of trustees is composed of one representative 
from each partner institution.  
KAGES: Dr. August Gomsi (Chair) 
TILAK: Univ. -Prof. Dr. Wolfgang Buchberger 
AUVA: Univ. -Prof. Dr. Harmut Pelinka  
BMGFJ: Dr. Wolfgang Ecker 
UMIT: Univ.-Prof.  Dr. Uwe Siebert 
PMU: Dr. Markus Schwarz 
LBG: Mag. Claudia Lingner 
Board meetings 2007: 
1st Board Meeting:  March 28, 2007 
2nd Board Meeting:  October 16, 2007 
Board of Trustees 
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The first board meeting dealt with the development of long-term strategies 
for the research programme on the LBI-HTA, enabling the integration of 
individual projects into the research programme. These long-term strategies 
were based on the strategy paper that was written in November 2006. Addi-
tionally, topics for 2007/08 were gathered, prioritized and agreed upon. 
The second board meeting in 2007 focussed on internal communication 
about the status of projects and discussion as to how partner organisations 
can contribute to projects. 
The Scientific Advisory Group (SAG) fulfils the task of scientific support 
and is selected - in equal shares – by the Ludwig Boltzmann Society and the 
members of the board of trustees.  It consists of  
Univ. Prof. Dr. Norman Waugh/ UK  
Univ. Prof. Dr. Alistair Gray/ UK  
Univ. Prof. Dr. Jürgen Windeler/ BRD 
Univ. Prof. Dr. Finn Borlum Kristensen/ DK 
Dr. Dagmar Lühman/BRD 
The first meeing of the Scientific Advisory Group took place on May 4th 
2007. Finn Borlum Kristensen was elected chairman of the group, and the 
role of the SAG was discussed (guidance or supervision). Furthermore, pos-
sible measures in methodological (literature research, rapid assessments, 
economic evaluations) and personal support through members of the SAG 
were discussed. In addition, there was a debate about the role of national 
HTAs in the context of international cooperation. 
1.4 Staff 
In addition to the organizational development of an interdisciplinary re-
search institute, the professional development and the specialisation of the 
team members are key issues. The former includes the exchange of perspec-
tives and methodologies, cooperation during projects, internal presentations 
and discussions, and internal evaluations in order to ensure high quality 
work. 
The Ludwig Boltzmann Society has initiated regular director meetings in 
order to increase both management capacities and identity building. Three 
meetings with the following leadership training topics have taken place: 
1. May 21st – 23rd: „corporate identity of LB-society and LB-institutes”, 
Laa/Thaya 
2. August 27th & 28th: „leadership & management”, St. Wolf-
gang/Wolfgangsee 
3. November 26th  & 27th: „team development”, Emmersdorf/Melk 
All researchers took part in the methodology development courses (see 2.1) 
„advanced bias spotting” (March 7th, 2007), „systematic hand search with 
Scopus” (October 25th, 2007), and „the application of GRADE” (December 
17th & 18th, 2007). 
1st board meeting: long 
term programme & 
project prioritization  
progress report and 
potential contribution 
of partners 
Scientific Advisory 
Group/SAG  
SAG's first meeting: 
election of the 
chairman 
goals: 
professionalisation, 
specialisation 
leadership-training  
for director 
increasing 
methodological  
know- how for 
researchers 
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Some researchers took part in the basic course „evidence based medicine: 
systematic reviews” (March 29th – 31st,2007 – Philipp Radlberger), or  in IS-
POR's courses „European Databases and Retrospective Database Analysis”, 
„Cost Estimation and Assessing Financial (Budget) Impact of New Health 
Care Technologies”, „cost effectiveness analysis alongside clinical trials” 
(Ingrid Zechmeister), „pharmacoeconomic modelling”, „event registration; 
utility measurements (preference-based techniques)”, „event registration 
transferability of cost effectiveness data between countries” (Philipp Radl-
berger), and „propensity scores” (Gerald Gartlehner). 
All members took part in the „power talking”, a rhetoric seminar (November 
19th & 20th, 2007 and January 22nd & 23rd, 2008), which dealt with language 
patterns and communication behavior. Ingrid Zechmeister also took part in 
media training about moderation skills and holding press conferences on 
September 15th 2007 in Cologne. 
As a part of his doctoral studies in national economic policy at the Vienna 
University of Economics and Business Administration Philipp Radlberger 
attended the classes „quantitative research methods”, „qualitative research 
methods”, „science theory”, and „research seminar in social policy”. Sabine 
Geiger-Gritsch is currently working on her thesis for a MPH at the UMIT. 
As an interdisciplinary institute the organisation of work is guided by pro-
fessional – assigned topic-specific – project management. 
Director (strategy and coordination): 
b Claudia Wild, Dr. phil.  
Research background: Communication Science, Political Science 
Deputy director: 
b Ingrid Zechmeister, Dr. rer. soc. oec., MA 
Research background: Health Economics  
Office: 
b Smiljana Blagojevic, Dipl.-Ing. 
Information specialist: 
b  Beate Guba, Mag. phil., MSc  
Senior Researcher: 
b Rosemarie Felder-Puig, Mag. rer. nat., MSc 
Reseach background: Psychology, Clinical Research 
b Gerald Gartlehner, Dr. med. , MPH  (since 2007/05/01) 
Research background: Medicine  
b Philipp Mad, Dr. med.  
Research background: Medicine 
b Stefan Mathis, Dr. med., Dipl.-Ing. (since 2007/05/01) 
Research background: Medicine 
b Sabine Geiger-Gritsch, Mag.pharm., Dr.scient.med. (since 2007/05/01) 
Research Background:  Pharmacy, Health Sciences 
b Philipp Radelberger, Mag. rer. oec.  
rhetoric course 
university education 
project management 
team members: 
director & deputy 
director 
office  
information specialist 
senior reseacher 
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Reseach background: Health Economics 
b Erwin Falkner (since 2007/05/01) 
Research Background: Biology 
Junior Researcher: 
b Tessa Langley, BSc (since 2007/10/15) 
Research Background: Economics and Economic History 
Trainees:   
b Tessa Langley, BSc (2007/07/16 - 2007/08/31) 
Research Background: Economics and Economic History 
b Elisabeth Breyer, Mag. phil. (since 2007/09/03) 
Research Background: Health Care Management 
External specialists were also engaged in projects: 
b Christopher Adlbrecht, Dr. med.  
Research background: Medicine 
b Thomas Langer, Dipl.-Soz. Wiss. 
Research background: Social Sciences 
b Andrea Korencan, Dr. med., Dr. phil.  
Research Background: Medicine 
b Erich Kvas, Dipl.-Ing. 
Research background: Biostatistics, Epidemiology 
b Brigitte Piso, Dr. med. , MPH 
Research Background: Medicine 
b Sonja Stammberger, Mag iur.  
Research background: Philosophy of Law 
b Bernhard Martin, Dr. Mag rer.soc.oec.  
Research background: Sociology, Journalism & PR 
The Ludwig Boltzmann Institute for Health Technology Assessment resp. its 
team members are members of the following international and national or-
ganisations: 
b  HTAi (Health Technology Assessment international),  
b INAHTA (International Network of Health Technology Assessment),  
b EUPHA (European Public Health Association),  
b German Network for Evidence Based Medicine, 
b German Society for promoting HTA, 
b Austrian Society for Public Health, 
b Platform Health Economics. 
In 2005 Claudia Wild was appointed to the Supreme Health Council (advi-
sory committee of the Health Minister), the Viennese Council of Bioethics 
and the Scientific Advisory Committee of the EBM-Working Group at the 
Austrian Federation of Social Insurances. Since 2007 she has been a board 
member of the Austrian Society for Public Health.  
junior researcher  
trainees 
external experts 
 
institutional 
memberships 
individual 
memberships 
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Ingrid Zechmeister is a member of International Health Economics Associa-
tion/IHE and of the „Fachhochschulentwicklungsrat für biomedizinische 
Analytik”. 
Erwin Falkner is member of the Tissue Engineering International & Regen-
erative Medicine Society (TERMIS) and the BiomatNet/The Biomaterial 
Network. 
Sabine Geiger-Gritsch is a member of the „German Society of Medical In-
formatics, Biometrics and Epidemiology” and of the „International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR)”. 
Beate Guba is a member of the „German Society of Medical Informatics, 
Biometrics and Epidemiology”, of the „European Association for Health In-
formation and Libraries”, of the „Arbeitsgemeinschaft für medizinisches 
Bibliothekswesen”and the „Forum österreichischer Medizinbibliothekarin-
nen und -bibliothekare” and since 2007 member of the „Verein zur 
Förderung der Informationswissenschaft”. 
Philipp Mad is member of the European Pathway Association EPA. 
1.5 Infrastructure 
The institute has a 150 m² office space (6 seperate rooms) and a 70 m² li-
brary/seminar room. The institute is equipped with 12 personal computer 
workstations. For 2008, 14 positions are planned. 
The library holdings amount to approximately 270 titles. Three electronic 
journals („Health Services Research”, Journal of „Public Health”, „ACP 
Journal Club” – in addition to the International Journal „Technology As-
sessment in Health Care” and „Zeitschrift für Ärztliche Fortbildung und 
Qualität”) were recently licensed. Moreover, access to several bibliographic 
databases has been established, e.g. Scopus (Elsevier) and Medline (Ovid). 
1.6 Highlights of the Year 
In January and March the LBI-HTA published its methods manuals. In the 
first part („external”), the conceptions and processes of the LBI-HTA are 
portrayed to present - in a transparent manner - its scientific basis. The pur-
pose of part 2 („internal”) is to illustrate and standardise the processes in-
volved in obtaining results, based on international examples. 
The production of a series of six papers on methodology topics was arranged 
with the weekly WMW (Wiener Medizinische Wochenschrift).  Most of the 
researchers of the LBI-HTA contributed to their creation between July and 
September 2007. The articles will be published over the course of 2008. For 
the assessment of medical procedures before their potential inclusion in the 
Austrian DRG catalogue, a standardised methodology using the assessment 
tool GRADE (see project description in PG 2) has been developed. Training 
and trials using the standardised methodlogy were carried out by all team 
members during November and December 2007. 
office space and 
equipment 
library 
focus methododology:  
manuals,  
series of method-
papers, 
GRADE adaptation for 
DRG-decision support 
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Lectures on „the support of decision-making in the health sector” were held 
reguarly and were well attended, attracting 25 – 40 visitors each month 
throughout the year. Because of strong interest on one occasion the lecture 
took place in the neighbouring rooms of the Society of Physicians. Also, the 
institute's monthly newsletters, which are being distributed to around 400 
people in Austria and Germany, are being met with interest. According to 
logfiles, 1200 to 1300 hits for the newsletter per month and 250 to 300 for 
project reports are registered. The media - newspapers and magazines in 
particular, but also radio - produced 13 reports on the institute or its mem-
bers during 2007. 
As a consequence of an overview project about international „Horizon Scan-
ning Programmes” in 2006, the content and procedural design of an EU-
wide newsletter on Emerging Technologies has been developed within the 
framework of EUnetHTA and in close cooperation with EuroScan. A Hori-
zon Scaning Programme on oncology is currently being developed in the 
LBI-HTA. It is due to be introduced in spring 2008 and run biannually in 
the future. Thus, in 2008, the LBI-HTA will be running horizon scannings 
and entering the international network of EuroScan. Together with an EU-
wide consortium under the lead of the Fraunhofer ISI (Institute of System 
and Innovation research), a system of indicators is currently being developed 
in order to assess medical technologies from the perspective of industry. 
Also, as regards the content of projects, close cooperations for structuring in-
formation transfer are increasingly fruitful. The health economic modelling 
of an HPV-vaccination programme for the Austrian system was established 
within 4 months, due to intense cooperation between the inventors of the 
British model (who provided the model free of charge) and Norwegian ex-
perts, who had already adapted it to the Norwegian system. There is also co-
operation with the University of Warwick in terms of modelling methods. 
Close cooperation with EUnetHTA has also been established following a 
project on „Avastin for age-related macula degeneration”. Extra work in re-
viewing the evidence (literature reviews) was avoided by means of same-
language (English) evidence tables: time and staff resources were saved.   
In September, in order to enhance exchange and knowledge transfer with the 
institute for Public Health, Medical Decision Making and HTA, at the pri-
vate University for Health Sciences, Medical Informatics, and Technology 
(UMIT), a two day meeting took place in Schladming, combined with some 
hiking for the two institutions’ staff. Methodological exchange, joint publi-
cations and personal development were agreed upon.  
On May 22th 2007 the LBI-HTA’s one-year anniversary was celebrated with 
partners and friends. The editor in chief of the ÖKZ, Mag. Andrea Fried, 
praised the work of the LBI-HTA’s first year.  
Most of the team members of the LBI-HTA participated in the 4th HTAi 
Conference in Barcelona, which brought together people with a common in-
terest in HTA, and enabled socialising with colleagues from all over the 
world. 
 
focus science 
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1.7 Research Programme: 5 Programme Lines 
Comprehensive assessments of health interventions & evidence-based 
health services research 
HTA can now look back on 20 years of methodological developments and in-
ternational harmonization. „Traditional” assessments answer questions on 
new/innovative or established medical interventions such as  
b Is the intervention effective, does it work? b For whom, which subgroup of patients? b At what cost? b How does the intervention compare with alternatives? 
Unlike traditional HTA, evidence-based health services are still young, but 
are based on the same basic research principles: systematic literature search 
and analysis, transparent presentation of sources, process and results and in-
terdisciplinary perspectives. In contrast to the results from the critical ap-
praisal of medical interventions, the results from health services research are 
deeply anchored in the health systems concerned and cannot be transferred 
as easily into other systems. The research field of evidence-based planning 
follows the approach of distinguishing between demand and need and of 
critically questioning the actual utilisation of health services.  
For this reason, the LBI-HTA as an HTA institute in a small country is de-
voted to bringing international HTA into our national context and to further 
developing methods of evidence-based health services research. 
Scientific support of health policy and decision-maker networks 
Policy-relevant decisions are traditionally reached on the basis of a consen-
sus of high-ranking experts in boards and committees. This process of exclu-
sively expert-based (so-called eminence-based) decision-making is highly 
prone to bias, conflict of interests and doctrine. It is the aim of the evidence-
based support of decision-making to collect and present recent research re-
sults and to provide a more rational and transparent input to the process of 
health policy decision-making independent of influences from interest 
groups. The aim is to shape the process in the long term by systematically 
questioning marketed information and by asking for sound evidence. 
It is the task of the scientific support of health policy and decision-maker 
networks to react rapidly to demand and to present the evidence in a trans-
parent and readable format to decision-makers. 
Health Technology Assessment in hospitals 
The informal „HTA in hospitals” network consists of a group of about 20 
high-ranking decision-makers (medical directors and quality managers) 
from nearly every Austrian hospital cooperation. The network meets 3 times 
a year (October, February, June) in order to receive informational HTA in-
put into 4 prevailing topics, to discuss them and to exchange ideas on regu-
latory and reimbursement issues. 
The task of the LBI-HTA is to coordinate the meetings, to ask for and collect 
current topics and to prepare the presentations. The format of the meetings 
is to present each topic from the HTA perspective and by an invited clinical 
expert, which subsequently leads into a structured discussion.  
programme line 1 
programme line 2 
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Scientific decision support of Health Ministry 
It is the task of the LBI-HTA to provide - on request - scientific support to 
different committees of the Austrian health ministry (BMGFJ, 
http://www.bmgfj.gv.at/):  
b to support the Medical Advisory Group for the maintenance of the Aus-
trian medical procedure classification (Austrian DRG Catalogue) with 
evidence analysis of new/innovative or established medical interventions. 
b to react to information enquiries in the Supreme Health Council (advi-
sory committee of the Health Minister). 
Public understanding and research transfer 
Quite often - steered by early media coverage - the demand for 
new/innovative health care interventions emerges, even before market ap-
proval or reimbursement. „Public understanding” is both the transfer of 
knowledge about market forces and about methods for critically questioning 
the evidence presented on effectiveness and cost-effectiveness, appropriate-
ness, and methodological support for the differentiation between new and 
innovative interventions. „Public understanding” is meant to contribute to a 
better understanding of true effectiveness and, at the same time, to a democ-
ratic shaping of benefit packages. 
The intention of „public understanding and research transfer” is to build up 
- through presentations, seminars, monthly newsletter, a user-friendly web-
page and search support - a critical mass of patients, journalists, representa-
tives of the health administration, academia etc. that questions the informa-
tion presented and asks for sound evidence before decision making. 
HTA-implementation: development and informing on effective policy in-
struments 
Evidence for the effectiveness and cost-effectiveness of numerous technolo-
gies and interventions can often only be presented after market approval and 
several years’ use under real clinical conditions. However, even then, ineffec-
tive technologies are widely spread and applied. Since it is ethically not jus-
tifiable to withhold true medical innovations from patients, and because 
pseudo-innovations absorb a lot of resources, taking new technologies under 
„surveillance” or „limited application” at specific medical centers is increas-
ingly frequently considered. Consequently, final decisions on reimburse-
ment are made only after patient-relevant outcome data become available. 
Methods for limited application and the assessment and appraisal of tech-
nologies and interventions after having obtained patient-relevant outcome 
data are still young. In this programme line, they will be further developed 
and applied. 
International cooperation / HTA Best Practice  
The EUnetHTA project started in January 2006 and is financed by DG 
SANCO/Health & Consumer Protection in the context of the „Community 
Action in the Field of Public Health” programme for 3 years (until 2008). 
The overall aim of EUnetHTA is to establish an effective and sustainable 
European network for HTA that informs policy decisions. Since all western 
countries and increasingly some new EU member states use HTA as a pol-
icy-tool, cooperation and collaboration is of utmost importance in order to 
reduce redundancies. 60 institutions from 31 countries cooperate within 
programme line 3 
programme line 4 
programme line 5 
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EUnetHTA. The reduction of overlaps and duplication, the transferability of 
HTA-reports within Europe and the strengthening of links with healthcare 
policy are the objectives of EUnetHTA. 
The LBI -HTA is co-initiator and leading partner in EUnetHTA and leads 
work package 7 in close cooperation with the French HAS/Haute Authorité 
de Santé. 
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2 Research Projects 
2.1 Projects & Activities in the 5 Programme Lines  
Effectiveness of intensified care for newborns by paediatricians 
Responsible for the project: Ingrid Zechmeister 
Duration: 05/2006 - 03/2007 
Research question/objective: Postnatal care of healthy newborns is managed 
in western countries in very different ways. With a high proportion of 
women delivering their babies in hospitals, the permanent postnatal medical 
care of paediatricians (with additional qualifications in neonatology and in-
tensive medicine) alongside the traditional care by midwives and obstetri-
cian is increasingly demanded, even in peripheral hospitals. It is the task of 
the project to research the evidence for the effectiveness of different models 
of care for healthy newborns. The research question is whether postnatal 
care (within 1-3 days after delivery) leads to better clinical outcomes with an 
additional permanent paediatrician or with the traditional model of patient 
visits by residential paediatricians in peripheral hospitals.  
Method: Systematic review  
Content: Paediatric care in Austria; models of different roles of paediatri-
cians in postnatal care of healthy newborns; international guidelines and 
recommendations; time-relevant diagnosis and therapies in postnatal care.  
Needs assessment for out-patient services in university hospitals 
Responsible for the project: Claudia Wild, Philipp Mad 
Duration: 05/2006 - 03/2007 
Research question/objective: University hospitals have to provide medical 
care and teaching functions: patients expect university hospitals to offer the 
latest medical treatments. Under increased budgetary and capacity con-
straints, out-patient services as well as in-patient care provision in university 
hospitals have to concentrate on specialized services not covered elsewhere. 
An assessment of the requirements (meeting the needs without accelerating 
the demand) of university out-patient services aims to investigate the ques-
tion of additional services and trends and tendencies in the provision of ser-
vices. The analysis of the data from 25 university hospital clinics offering 
outpatient services (University Hospital of Innsbruck) will support the 
planning of these services in the future.  
Method: Systematic review and (retrospective) data analysis  
Content: Systematic review of international approaches to planning and re-
structuring out-patient services at university hospitals; data analysis of out-
patient services in the University Hospital Innsbruck: quantity frequencies 
of services delivered; description of care „environment”: provision of services 
by physicians and specialists in the surrounding area; data analysis of fre-
quent services with low specialisation for their need for vocational training 
and research.  
 
programme line 1 
programme line 1 
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HER2 testing 
Responsible for the project: Claudia Wild 
Duration: 01/2007 - 06/2007 
Research question/ objective: The availability of a targeted therapeutic anti-
body (trastuzumab) for HER2 positive tumours requires HER2 testing in 
order to reliably identify patients who might benefit from trastuzumab 
treatment. This is because only patients who have the potential to benefit 
from the treatment (positive clinical effects) ought to receive Herceptin, but 
also because of its severe side-effects (grade 3 or 4 cardiotoxicity), and high 
costs. The research question is: What is the gold standard for diagnosing 
HER2 positive tumours? Which is the most accurate and reproducible 
method for identifying the candidates for potential therapy with monoclonal 
antibodies, and are the applied tests reliable for selecting HER2 positive pa-
tients?  
Method: Systematic review of studies on questions of validity and standardi-
zation of the 2 most commonly used methods IHC (immuno histochemistry) 
and FISH (fluorescence in situ hybridization). Also, the inter-observer and 
the inter-laboratory concordance esp. in the diagnosis of borderline results.  
Content: The review discusses - systematically - the HER2 testing results of 
more than 23 000 specimens, achieved in local, central or reference laborato-
ries. IHC results show much greater variability than FISH test results, par-
ticularly for the FISH negative cases. The results of most presented studies 
indicate that high-level HER2 amplification and an IHC score of 3+ will 
identify HER2 positive breast carcinoma; the low-level amplification and/or 
IHC score of 2+ should be carefully interpreted. There is agreement that the 
most (cost-)effective testing strategy is to screen all patients with IHC, fol-
lowed by FISH for IHC of 2+ (or of 2+ and 3+). Findings concerning dif-
ferent results from local/central laboratories suggest moderate inter-observer 
and inter-laboratory reliability of test results. A volume/experience relation-
ship is observed. 
Development of determinants for a scientific monitoring and evalua-
tion of the Mammography Screening Model Salzburg 
Responsible for the project: Philipp Radlberger 
Duration: 10/2006 -07/2007 
Research question/objective: During the last 20 years mammography screen-
ing programs for 50-69 year old women have grown in importance and 
nowadays are even directed in their implementation by EU-Guidelines. Such 
mammography screening programs have important clinical and economic 
consequences: With high quality assurance one can expect an early detection 
of breast cancer and a relative reduction of breast cancer mortality of 20-
30%, which corresponds to an absolute reduction of 2-3%. In order to evalu-
ate the cost effective implementation of such programs, a catalogue of de-
terminants containing clinical as well as organisational and economic pa-
rameters of result evaluation is required. In view of performance, Salzburg's 
mammography screening model shall be scientifically supported by the de-
velopment of a determinants catalogue, based on long term-experience of 
other countries such as Canada, Great Britain or Sweden.  
Method: Overview and systematic analysis of best practice models and per-
formance determinants 
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Content: Systematic review of international performance determinants, 
guidelines for clinical and organisational quality assurance and for certifica-
tion of breast cancer assessment centres; catalogue of performance determi-
nants and cost analysis. 
Statins: A comparison between predicted and actual effects on inpatient 
care in Austria - part 2 
Responsible for the project: Ingrid Zechmeister  
Duration: 2006-2007 
Research question/objective: Since the 1990s statins have been increasingly 
applied for the prevention of cardio-vascular diseases. In clinical studies 
they have been shown to be effective. Compared to placebos, a relative risk 
reduction with respect to mortality and morbidity has been demonstrated. 
Apart from the clinical benefit, it has been expected that the use of statins 
will reduce the number of cardio-vascular interventions (such as coronary 
artery bypass grafting) and thus will result in decreasing hospitalisation. 
This should eventually guarantee favourable cost-effectiveness results. The 
question to be answered is whether there is empirical evidence to support 
this hypothesis, not only on the basis of clinical studies but under real condi-
tions of use in Austria.  
Method: In part 1 of the project a systematic review of economic evaluations 
which addressed statin therapy for the secondary prevention of cardio-
vascular diseases was carried out. The results can be downloaded from 
http://epub.oeaw.ac.at/ita/ita-projektberichte/d2-2b30.pdf. In part 2 a deci-
sion analysis model which was developed for the UK will be adapted with 
Austrian utilisation and cost data.  
Content: Conducting a workshop and adapting the UK model in cooperation 
with the University of Sheffield and with the Federation of Austrian Social 
Security Institutions. Based on the results, in part 3 of the project the impact 
of statin therapy on actual hospital interventions in Austria will be analysed 
empirically.  
Avastin for age-related macular degeneration: Safety aspects 
Responsible for the project: Claudia Wild 
Duration: 07/2007 – 10/2007 
Research question/objective: Age-related macular degeneration is a poten-
tially blinding disease, caused by neovascularisation, a pathological growth 
of blood vessels in the retina. In recent years the management of AMD has 
been significantly changed by new treatment options, such as 
VEGF/vascular endothelial growth factor, which inhibits the growth. 
Ranibizumab/Lucentis was approved for the treatment of AMD in spring 
2007, the almost identical drug Bevacizumab/Avastin is currently only ap-
proved for the treatment of colorectal cancer, but is being used extensively in 
an „off-label” manner in ophtalmological practice, because of its proven 
equal effectiveness. Avastin has not undergone rigorous clinical trials or 
comparative research. Avastin is considerably less expensive. The aim of this 
assessment is to systematically analyse the side-effects and safety aspects of 
Avastin in the treatment of AMD. 
Method: Systematic search and analysis of clinical studies on safety issues 
and Avastin´s profile of side-effects; rapid assessment in cooperation with 
six European countries. 
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HPV vaccination: Cost-effectiveness analysis 
Responsible for the project: Ingrid Zechmeister 
Duration: 08/2007 – 12/2007 
Research question/objective: Various epidemiological observations have 
shown a correlation between infections with certain human papilloma vi-
ruses and the development of cervical carcinoma, resp. carcinoma in its early 
stages. Recently, though only secondary to the successful screening pro-
grammes for early detection (pap smear tests), immunization against some 
high-risk HPV types became possible. Now, after the approval of the vac-
cines, health care decision-makers are required to decide, if and, if so for 
which sub-groups the vaccination should be financed by public resources. 
Significant criteria are the potential for actually preventing disease and 
death (the anticipated health effect) and accordingly, the expected costs and 
cost-reductions. As a basis for sound information, health economic models 
have been developed in other countries. This assessment conducts a cost-
effectiveness analysis for HPV immunization for the Austrian context and is 
intended to make a prognosis of the expected impact of a vaccination on de-
fined health-parameter life-years saved, avoided events and costs in com-
parison to screening alone. 
Method: Adaptation of the Norwegian/UK health economic HPV model and 
calculation of different vaccination strategies. 
Clinical applications of tissue engineering: An outline of the field of re-
search, Austrian aspects and critical analysis of selected approaches 
Responsible for the project: Erwin Falkner 
Duration: 05/2007 – 05/2008 
Research question/ objective: Tissue Engineering (TE) is defined as the use 
of autologous or allogenous cells, mostly in a matrix of proliferation and/or 
differentiation enhancing environment to stimulate tissue and organ regen-
eration in patients of varying clinical conditions. State of the art of TE pro-
jects vary from prevalent clinical usage of in vitro cultivated autologous 
chondrocytes for knee defects to future visions of whole organ systems. Bene-
fits and risks for patients, advantages to common therapies as well as costs 
have been evaluated only for certain aspects of the field, yet. The goal of the 
project is a review of the current international state of TE, with a focus on 
the analysis of structural questions on Tissue Banks in the Austrian theatre, 
furthermore to evaluate selected fields of application critically in the means 
of patient value. 
Method: Systematic investigation of TE applications and analysis of current 
evidence of its use; classification into 6 categories (conceptualized, experi-
mental, animal testing, pre-clinical phases, rife clinical application, abjected 
onsets); assessment of selected TE approaches with clinical relevance in Aus-
tria; analysis of Austrian guidelines for tissue banks, structural conditions, 
assurance of quality. 
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Nonspecific acute and chronic back pain: Evidence-based diagnosis and 
treatment in practice – options and limitations 
Responsible for the project: Rosemarie Felder-Puig 
Duration: 06/2007 – 04/2008 
Research question/ objective: Nonspecific acute and chronic back pain, pri-
marily in the low back, are amongst the most frequent pain problems, al-
though estimates of their prevalence and economic consequences vary 
greatly between studies. Since 2000 there has been increasing support in the 
literature for favouring activating and educational therapies over passive and 
surgical concepts. Although a number of systematic reviews, HTAs and 
guidelines are available for diagnosis and treatment of back pain, it seems 
that the evidence often does not inform everyday clinical decisions of physi-
cians and/or acceptance and compliance of patients. Nevertheless, there is 
widespread agreement that adherence to evidence-based practice will help 
improve back pain patient outcomes and reduce costs. The aim of this HTA 
is to provide a systematic review of current best evidence of effective preven-
tion strategies and diagnostic and therapeutic modalities. We will address 
discrepancies in recommendations across guidelines, their methodological 
quality and the fact that most of them are monodisciplinary rather than 
multidisciplinary. Further, we will broach the issue of scarce availability of 
high quality information for patients.  
Method: Evaluation of current German-language guidelines and comparison 
to results of recent meta-analyses, systematic reviews and HTAs; collection 
of Austrian epidemiological data; experts' opinions about practice and dis-
crepancies. 
Outpatient cardiac rehabilitation 
Responsible for the project: Gerald Gartlehner, Brigitte Piso 
Duration: 11/2007 – 09/ 2008 
Research question/ objective: Cardiac rehabilitation is an important thera-
peutic intervention to facilitate the reintegration of patients into society, 
family and work following acute cardiac events. Phase I of the cardiac reha-
bilitation consists of the early mobilization during the hospital stay after an 
acute cardiac event. Phase II consists of various other interventions, lasting 4 
to 6 weeks, and administered in an outpatient or inpatient setting. The ob-
jective of this systematic review is to assess the comparative efficacy and 
safety of inpatient and outpatient cardiac rehabilitation in defined popula-
tions. Furthermore, the report will examine how health systems, compared 
to the Austrian one, have evaluated the quality of cardiac outpatient reha-
bilitation. Based on these findings, the report will discuss valid outcome pa-
rameters that could be used to evaluate cardiac outpatient facilities in Aus-
tria. 
Method: Systematic review. 
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Clinical pathways: Assessing outcome and effectiveness 
Responsible for the project: Philipp Mad 
Duration: 07/2007 – 04/2008 
Research question/objective: In recent years clinical pathways have been in-
creasingly introduced in western countries as instruments for quality assur-
ance. A survey among users of clinical pathways in 23 countries found that 
clinical pathways are mainly perceived as tools for improving multidiscipli-
nary approaches to enhance quality and evidence based care. These days, 
clinical pathways are primarily applied in acute health care settings. Despite 
worldwide increased implementation of clinical pathways many questions 
remain as to their actual impact: on the one hand there are uncertainties 
about their exact definition, scope and profile in contrast to other instru-
ments of quality assurance. On the other hand, their intention, value and 
measurable benefit is not entirely clear. The objective of this assessment is to 
look closely at the potential to evaluate the impact of clinical pathways in 
general and to identify outcome-indicators on the basis of previous evalua-
tions, and to give an overview of the effectiveness of clinical pathways as 
measured by these outcome-indicators 
Method: The appraisal orientates itself along the methodology developed by 
the propositions of the Cochrane Effective Practice and Organisation of Care 
(EPOC) Group for measuring the impact of organisational, regulative, edu-
cative and financial interventions in health. 
Alcohol therapy in Austria compared to other countries: status quo and 
alternatives using the example of the region of Salzburg  
Responsible for the project: Philipp Radlberger 
Duration: 10/2007 – 07/2008 
Research question/objective: In the field of addiction therapy standardised 
treatment strategies are often difficult to establish. Alcohol dependent pa-
tients vary in terms of the degree and the character of their addictions. Alco-
hol addicts also differ in motivation, therapy adherence and social environ-
ment. It can be difficult to identify their key characteristics, which is neces-
sary for assigning them to the correct patient groups. Different countries 
and their institutions try to handle these problems in various ways. Regional 
and national authorities are searching for ways to optimise strategies and 
programs of treatment. So far we cannot say to what degree such attempts 
are successful. Some few pharmaceutical treatments as well as psychothera-
peutic treatment are widely seen as promising options. Apart from that there 
is a wide range of different approaches which all have in common: That 
there is very little existing evidence about efficiency and effectiveness. From 
a clinical as well as from an economic perspective, establishing a consistent 
system of alcohol therapy is an enormous challenge. 
Method: Systematic review, literature and data analysis 
Content: Comparing structures of services in the region of Salzburg with in-
ternational approaches as well as real designs of alcohol therapy institutions. 
Research and evaluation of international evidence on organisation and cost-
effectiveness of models of therapy for alcohol addict people. 
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Methods manual 
Responsible for the project: Gerald Gartlehner  
Duration: 09/2006 – 03/2007 
Research question/ objective: HTA promotes 3 principles: Systematic litera-
ture search, analysis and appraisal, transparent presentation of the HTA 
process and methods, and an interdisciplinary perspective. New medical in-
terventions in particular are often explosive since different interest groups - 
naturally - assess them differently in terms of innovation/medical advance 
and „stage of maturity” (still experimental or qualified for broader diffu-
sion). Since HTA is an instrument of critical health policy support, it is not 
free of conflicts. A manual is intended to facilitate the understanding of our 
work processes. The intention of an external manual is to present an over-
view of research methods and tools for collecting, selecting and interpreting 
the materials and literature for systematic reviews. The manual is intended 
to make the routes to the results reproducible. The intention of the internal 
manual is the standardization of processes and of terminology, and to sup-
port research with toolkits such as templates for the external and internal 
validity of studies, evidence tables, classification schemes etc. The manual 
contains a special focus on methodological questions concerning rapid as-
sessments of new/innovative technologies.  
Method: Systematic synopsis of HTA methods and processes  
Content: Definitions, Methods for literature search and classification, Selec-
tion criteria, data abstraction, appraisal.  
Development, evaluation and application of a method to assess indi-
vidual medical services 2008 
Responsible for the project: Gerald Gartlehner, Rosemarie Felder-Puig 
Duration: 07/2007 – 03/ 2008 
Research question/ objective: Each year, the Austrian Ministry for Health, 
Family and Youth receives suggestions for numerous new medical interven-
tions to get reimbursed. The aim of this project is to develop a standardized 
tool to evaluate the scientific evidence for these interventions. The project 
consists of two parts. The objective of the first part (July - December 2007) is 
the development of an algorithm to systematically evaluate the efficacy and 
safety of interventions suggested for inclusion in the MEL (individual medi-
cal services) catalogue. A preliminary algorithm, based on the methods 
manual of the LBI-HTA, will be tested by multiple persons and refined 
based on consensus. During the second part of the project (January - March 
2008), 20 interventions that were prioritized by the Ministry of Health for 
inclusion into the MEL catalogue will be systematically evaluated. The as-
sessments will be based on systematic reviews for each intervention and a 
summary of the scientific evidence according to the GRADE scheme. 
Method: Development of an algorithm and a report format; systematic re-
views and summary of evidence according GRADE. 
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Health Technology Assessment in hospitals 
Responsible for the project: Claudia Wild 
Duration: 3 x p.a. 
February 27th 2007 - Topics 
b Natalizumab in the treatment of multiple sclerosis 
b Lucentis and the treatment of age-related macular degeneration 
b Photoselective laser vaporization of prostate 
b Robotics in urology 
b Cancer treatment: HER2 diagnostics, Herzeptin®, monoclonal antibodies 
b Drug eluting stents: An update 
b Kyphoplasty: An update 
 
Method: presentations 
May 22nd 2007 - Topics 
b Photodynamic therapy of malign intestinal stenosis  
b Palliative Care 
b HPV  
b Y-90-Octreotid and Lu-177-Octreotid in the treatment of metastasizing 
neuroendocrine tumours in the gastrointestinal tract 
b Human growth hormones  
 
Method: presentations 
Oktober 16th 2007 - Topics  
b Enzyme substitution therapy 
b Immune adsorption 
b Avastin in the treatment of age-related macular degeneration 
b  Evaluation and application of a method to assess individual medical ser-
vices 2008 
 
Method: presentations 
Philipp Radlberger developed an evaluation scheme for the Salzburger Ge-
sundheitsfonds SAGES (funding agengcy). It is used jointly by experts of the 
government in Salzburg and regional social insurance companies in order to 
assess projects which receive annual subsidies for measures for relieving 
hospital efforts. The results of the evaluation were submitted to the govern-
ment of the region of Salzburg. 
Claudia Wild consulted the Austrian ministry for health, family and youth 
by submitting reports about 
b cardiac contractility modulation after a request from the DRG-
Committees – May 2007 
b volume and outcome in oncology after a request from the minister – June 
2007      
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b extracorporeal shockwave therapy – new and existing evidence after a re-
quest from the DRG-Committee (in cooperation with Bernhard Martin) – 
December 2007 
In programme line 3 the following activities take place on a regular basis: 
public seminar-series („decision support in health care”), semi-public train-
ings on methodology, HTA newsletter and website. 
Responsible for the project:  Beate Guba 
Health economics apart from the market-based mainstream 
01-16-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Univ.-Prof. Dr. Bernhard J. Güntert, MHA 
HEK/Commission for Evaluation of Pharmaceuticals: Methods, workflows, 
assessment procedures 
02-19-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Univ.-Prof. Dr. Markus Müller 
Ethics instead of technology assessment? Advising on biomedical matters 
03-20-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Alexander Bogner, PhD 
Antibiotic resistance 
04-18-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Univ.-Prof. Dr. Helmut Mittermeyer 
Progress in oncology: The role of modern cancer registries 
05-07-2007 | 16:00 | Gesellschaft der Ärzte in Wien (Billrothhaus) 
Univ.-Prof. Dr. Dieter Hölzel 
Evidence-based consumer information 
09-19-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Hilda Bastian 
The Austrian disease management programme diabetes 
10-23-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Prim. Dr. Gert Klima 
Is there a link between progression free survival and overall survival in me-
dicinal breast cancer therapy? 
11-29-2007 | 16:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Univ.-Prof. Dr. Uwe Siebert 
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Bias spotting advanced training course 
03-07-2007 | 09:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Dr. Monika Lelgemann, MSc, University of Bremen, Univ.-Prof Dr. Norbert 
Donner-Banzhoff, University of Marburg 
Relative effectiveness 
05-08-2007 | 14:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Dr. Fabian Waechter, MSc 
Systematic hand search with Scopus 
10-25-2007 | 15:00-17:00 | Ludwig Boltzmann Institute of Health Technol-
ogy Assessmement 
Laura Morgan (via Skype) 
Evaluation of individual medical services using GRADE 
12-17-2007 | 09:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Univ.-Prof. Dr. Holger Schünemann 
Developing an Austrian decision analytic model for statin treatment of 
CHD patients 
06-13-2007 | 09:00 | Ludwig Boltzmann Institut of Health Technology As-
sessment 
Dr. Ingrid Zechmeister, Roberta Ara, BSc, MSc, Sue Ward, BA, Dr. Gott-
fried Endel 
The monthly HTA-Newsletter appears since May 2006 at LBI of HTA.  
Responsible fort he project: Claudia Wild 
Duration: 10 x p. a. 
The website is being held up-to-date on a daily basis. 
Responsible for the website: Beate Guba 
Procedures undergoing evaluation – kyphoplasty and vertebroplasty 
Responsible for the project: Rosemarie Felder-Puig  
Duration: 2006 – 2009 
Research question/objective: Conservative treatment of vertebral compres-
sion fractures (VCF) in older patients includes bed rest and analgesics fol-
lowed by mobilisation and eventually, the use of a bodice. Alternatively, two 
minimally invasive procedures – percutaneous kyphoplasty (KP) and verte-
broplasty (VP) – are available. Patients with osteoporotic VCF and chronic 
pain in particular may benefit from these techniques. VP, which is less 
costly than KP, induces quick pain relief. KP also leads to a quick pain re-
duction.  In addition, it is meant to be safer and to restore vertebral height, 
as well as guaranteeing a lower risk of refractures. However, there is insuffi-
education and training 
other events 
HTA newsletter 
website 
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cient evidence about these benefits for patients. Specifically, long-term re-
sults and cost-effectiveness data are scarce or altogether absent. A study con-
ducted at the Austrian AUVA hospitals should be able to provide data about 
the effectiveness of KP and VP under real conditions. The study will be per-
formed in co-operation with other clinics (University Clinics of Orthopae-
dics at Vienna and Graz, Hanusch Hospital Vienna) and will collect data 
prospectively for a time interval which has yet to be defined.  
Method: Empirical study, application study  
Content: Co-ordination of participating institutions; production of study 
documents (protocol, CRF, patient consent form, application to Ethics 
Committee, registration); implementation, data insertion and analysis; pres-
entation of results and publication.  
Horizon scanning in oncology: Method development and application 
for the early identification and assessment of new and emerging drugs 
Responsible for the project: Sabine Geiger-Gritsch 
Duration: 05/ 2007 – 05/ 2008 
Research question/objective: The scientific and medical progress in oncology 
quickly leads to the introduction of new medicines. In addition, the devel-
opment of new therapy modalities, the so-called „targeted therapies” such as 
monoclonal antibodies or tyrosine kinase inhibitors („small molecules”), re-
sults in a rapid increase in the medicine costs in oncology in hospitals. The 
fast and to some extent uncontrolled use of these expensive cancer medicines 
in clinical practice, as well as their increasing off-label use, has an effect on 
hospital drug budgets. The development of a „Horizon Scanning System” for 
the early identification and evaluation of new drug therapy concepts in on-
cology, i.e. before a routine introduction to cancer treatment, should pur-
posefully prepare hospitals (respectable drug commissions) for new cancer 
medicines and should contribute to rational decision making as well as sup-
porting the prospective budget planning. The aim of this project is to design 
a guideline, firstly for the systematic collection of information (sources for 
identification and criteria for prioritization) about new drugs in oncology 
(incl. existing drugs with extension of indication) relevant for hospitals, and 
secondly, for their early evaluation on the basis of defined parameters. 
Method: Database search; analysis of information sources, criteria for priori-
tization and parameters for evaluation. 
Key factors in implementing, performing and analysing registries for 
cardiovascular, neurological and spine specific questions 
Responsible for the project: Stefan Mathis 
Duration: 06/ 2007 – 03/2008  
Research question/ objective: While randomised controlled studies evaluate 
health technologies in selected patients, registries cover data from medical 
interventions in real life situations. Registries are expected to contribute ad-
ditional information about clinical but also socio-political aspects. However, 
it is not clear for what kind of questions registries are the adequate methodi-
cal approach and what are the key factors for implementing, performing and 
analysing registries. The object of this project is to give an overview of cur-
rent registries in cardiovascular, neurological and spine specific fields, to 
analyse the kind of clinical and socio-political questions being addressed, 
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and to identify practical and methodical best practice models and key factors 
for implementing convincing registries. 
Method: Systematic search for registries and adequate methodical literature; 
systematic analysis of the registries' objectives. 
EUnetHTA - Application studies and surveillance systems in the EU 
Responsible for the Project: Rosemarie Felder-Puig  
Duration: 2006 – 2008 
Research question/ objective: Since the actual effectiveness and cost-
effectiveness of many of the health technologies that are introduced in 
health care systems cannot be evaluated before broader application under 
real conditions, many countries either release technologies that are not fully 
assessed or require post-marketing follow-up studies. An alternative is the 
requirement to monitor the use and the outcome of a technology. For this 
reason, some countries have started to set up „registries” or „application pro-
tocols” in order to keep some health technologies (often surgical or costly in-
terventions) under surveillance before broader diffusion takes place and un-
til decisive evidence is available. The objective of Strand A of Work Package 
7 of EUnetHTA is to provide tools that enable countries to monitor the de-
velopment of emerging, new or established health technologies and to share 
data and results of this monitoring.  
Method and content: Overview of existing monitoring tools (application 
studies, registries, etc.) and of technologies that are currently being moni-
tored with these tools; development of commonly shared monitoring tools 
that are relevant to the different technologies considered and adapted to the 
resources available in institutions in charge of technology assessment; pilot-
ing of one monitoring tool and testing the feasibility of pooling data from 
different countries using a common monitoring tool.  
EUnetHTA - Emerging technologies (part 2): EU newsletter 
Responsible for the project: Claudia Wild  
Duration: 10/2006 – 07/2007 
Research question/ objective: Work package 7 of EUnetHTA is subdivided 
into two strands: The development of a structured information service rele-
vant to policy makers on high-volume, costly and rapidly developing emerg-
ing technologies is the task of WP 7/strand B. The work will be carried out 
in close cooperation with EuroScan. On the basis and experiences of existing 
„emerging tech”- programmes (part 1), structures and processes for setting 
priorities in the selection of technologies as well as a first pilot newsletter 
will be developed, which, after critical evaluation by the WP partners will be 
distributed on a regular basis after 2008.  
Method: Design of content and graphics  
Content: Design of content and graphics; synthesis and specification of pri-
ority setting criteria for topic selection; specification of processes (editorial 
board, frequency etc.); piloting; revision and finalisation; regular production 
and distribution. 
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InnoHTA: HTA-methodology for innovative healthcare technologies - 
feasibilty of indicators  
Responsible for the Project: Claudia Wild 
Duration: 01/2007 – 12/2008 
Objective: In January 2007 DG SANCO commissioned a project for assess-
ing (fields of) technologies in the earliest stages of development. The project 
leader is the Fraunhofer Institute for Systems and Innovation Research 
(ISI), other partner institutions are University of Luebeck, University of 
Nottingham, the Danish National Board of Health, Health Statistics and 
Medical Technologies State Agency, Latvia, and the GSF - Forschungszen-
trum für Umwelt und Gesundheit GmbH, Germany. The project should lead 
to a set of a limited number of realistic indicators. These indicators are seen 
as a tool for assessing strenghs and weaknesses of (fields of) technologies, de-
spite a high degree of uncertainty. Inno-HTA tries to bring in a broad per-
spective of HTA-relevant aspects and potential actor groups. Questions re-
lated to data validity and realistic value of information about the quality of 
technologies will be crucial for the choice of the indicators. 
Method: Design of three different case studies according and comparing the 
results with those of three other studies and testing a set of indicators on the 
basis of these examples 
2.2 Publications  
Gartlehner G. (2007): (Internes) Manual. Abläufe und Methoden. Teil 2. 
HTA Projektbericht Nr. 006. 
Radlberger P., Wild C. (2007): Mammographiescreening. Evidenzbasierte 
Evaluationshilfe für organisierte Programme. HTA Projektbericht Nr. 007. 
Wild C., Mad P., Langer T., Guba B., Kvas E., Reichelt Ch., Adlbrecht Ch. 
(2007): Rolle und Positionierung der Ambulanzen von Universitätskliniken 
im Gesundheitswesen, Teil 1: Literaturanalyse & strukturierte Expertenbe-
fragung, Teil 2: Methodenbeschreibung zur empirischen Analyse von Ambu-
lanzleistungen. HTA Projektbericht Nr. oo5. 
Wild C. (2007): (Externes) Manual. Selbstverständnis und Arbeitsweise. Teil 
1.  HTA Projektbericht Nr. 003. 
Zechmeister I., Wild C., Koller D., Langer T. (2007): Neonatologische Erst-
versorgung von Neugeborenen ohne vorab bekanntes Komplikationsrisiko. 
Ansätze für eine evidenzbasierte Versorgung in der Steiermark. HTA Pro-
jektbericht Nr. oo4. 
Korencan A., Wild C. (2007): Testing for HER2 Positive Breast Cancer. 
HTA Projektbericht 008. 
Zechmeister I., Freiesleben de Blasio B., Radlberger P., Wild C., Kvas E. 
(2007): Ökonomische Evaluation der Impfung gegen humane Papillomavi-
ren (HPV-Impfung) in Österreich. [Economic evaluation of HPV vaccinati-
on in Austria]. HTA Projektbericht Nr. 009. 
Wild C., Kvas E.  (2007): Medikamentfreisetzende Stents bei Koronarinter-
ventionen im Vergleich zu nicht beschichteten Stents. Rapid Assessment 
LBI-HTA Nr. 001. 
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Wild C., Adlbrecht, Ch. (2007): Avastin® bei Altersbedingter Makuladege-
neration. Analyse der Sicherheit & Nebenwirkungen. Rapid Assessment 
LBI-HTA Nr. 002. 
Adlbrecht C. (2007) : Fotoselektive Vaporisation. HTA in Krankenanstalten,  
Decision Support Document LBI-HTA Nr 001. 
Adlbrecht C. (2007): Radiopeptidtherapie. HTA in Krankenanstalten,  Deci-
sion Support Document LBI-HTA Nr. 002. 
Mad P. (2007): Photodynamische Therapie Palliation maligner Stenosen im 
Verdauungstrakt, HTA in Krankenanstalten,  Decision Support Document 
LBI-HTA Nr. 003. 
Knapp, M., McDaid, D., Amaddeo, F., Constantopoulos, A., Oliveira, M., 
Salvador-Carulla, L., Zechmeister I. and the MHEEN group.  (2007): Fi-
nancing Mental Health Care in Europe. Journal of Mental Health 16 (2): 
167-180. 
Zechmeister I. und  Österle A. (2007): Informelle Betreuung psychisch er-
krankter Menschen: Schafft das österreichische Pflegevorsorgesystem adä-
quate Voraussetzungen? [Informal Care of People with Mental Disorders: 
Does the Austrian Long-Term Care System Provide Adequate Support?] 
Neuropsychiatrie 21 (1): 29-36. 
Felder-Puig R., Mad P., Gartlehner G. (2007): Diagnostische Studien [Di-
agnostic studies]. Wiener Medizinische Wochenschrift, accepted. 
Puig S., Staudenherz H., Felder-Puig R., Paya K. (2007): Imaging of appen-
dicitis in children and adolescents: Useful or useless? A comparison of imag-
ing techniques and a critical review of the current literature. Seminars in 
Roentgenology, in print 
Gartlehner G., Wild C., Mad P. (2007): Systematische Übersichtsarbeiten 
und Meta-Analysen, Wiener Medizinische Wochenschrift, accepted. 
Guba B. (2007): Systematische Literaturrecherche. Wiener Medizinische 
Wochenschrift  2007,  accepted. 
Mad P., Felder-Puig R., Gartlehner G. (2007): Randomisiert kontrollierte 
Studien [Randomized controlled trials]. Wiener Medizinische Wochen-
schrift,  accepted.  
Mathis S., Gartlehner G. (2007): Kohortenstudien. Wiener Medizinische 
Wochenschrift, accepted. 
Wild C., Gartlehner G. (2007): Health Technology Assessment. Wiener 
Medizinische Wochenschrift, accepted. 
Wild C. (2007): Polymorphismen-Screening: genetic testing for predisposi-
tion. Guidance for technology assessment. Poiesis & Praxis, International 
Journal of Ethics of Science and Technology Assessment, in print. 
Wild C., Langer T. (2007): EU-wide newsletter on emerging technologies: 
Informing and supporting health policy early. Health Policy, accepted. 
Zechmeister  I., Wild C., Langer T. und Koller. D. (2007): Pädiatrische 
Erstversorgung in peripheren Geburtskliniken: Ansätze für eine evidenzba-
sierte Versorgungsplanung für Neugeborene ohne vorab bekanntes Geburts-
risiko. [Neonatal Care in Peripheral Birth Clinics: An Approach to Evi-
decision support 
documents   
manuscripts in  peer-
reviewed journals  
submitted, accepted or 
in print 
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dence-based Health Care Planning for Low-risk Births]. Monatsschrift Kin-
derheilkunde, submitted. 
Zechmeister I. (2007): Einsatz von Statinen zur Sekundärprävention kardio-
vaskulärer Erkrankungen: Ein systematischer Review gesundheitsökonomi-
scher Analysen. [Statins fort the secondary prevention of cardio-vascular 
diseases:  A systematic review of economic evaluations.] Gesundheitsökono-
mie und Qualitätsmanagement, submitted. 
Zechmeister  I., R. Kilian und D. McDaid. (2007): Is it worth investing in 
mental health promotion and prevention of mental illness? A systematic re-
view of the evidence from economic evaluations. BMC Public Health, in 
print. 
Zechmeister I., Radlberger, P. (2007): Gesundheitsökonomische Evaluation. 
[Economic evaluation of health care.] Wiener Medizinische Wochenschrift, 
accepted. 
Felder-Puig R. (2007): Das ärztlich-therapeutische Gespräch: Die Effektivi-
tät verstärkter Arzt-Patienten-Kommunikation. Newsletter der Österr. Ges. 
f. Public Health 2007: 1. 
Felder-Puig R. (2007): Aus für klinische Studien?. Österreichische Ärztezei-
tung  2007; 12: 48-49. 
Guba B. (2007): Bibliotheksangebote in Universitätsportalen - Chancen und 
Risiken. Mitteilungen der VÖB 60(2): 30-38. 
Wild C. (2007): Unabhängige klinische Studien. Wiener Wissenschaftsfonds 
startet Förderlinie.  In: ÖKZ/Österreichische Krankenhauszeitung, 1:  16 
 Wild C. (2007): Horizon Scanning, In: ÖKZ/Österreichische Krankenhaus-
zeitung (04):  16 
Wild C. (2007): FDA Warnung zu Erythropoietin. In: ÖKZ/ 
Österreichische Krankenhauszeitung (07):  11 
Wild C. (2007): Evaluierung der österreichischen Mammographie-Screening 
Pilotprojekte? In: ÖKZ/Österreichische Krankenhauszeitung (11): 16 
Wild C. (2007): Drug Eluting/Medikamentenbeschichtete Stents. Aufre-
gung, Kalmierung und vorliegendes Wissen. In: ÖKZ/Österreichische 
Krankenhauszeitung (12): 16. 
Wild C., Zechmeister I. (2007): Gestaltung von Gesundheitspolitik: Rationa-
litäten einer gerechten Verteilungspolitik - Health Technology Assessment 
als Mittel zum Zweck. Kurswechsel 2/2007. 
Zechmeister, I. (2007). Psychische Gesundheit zahlt sich aus!? Evidenz zur 
Wirtschaftlichkeit von ‚Mental Health’ Förderungs- und Präventionsmaß-
nahmen [Is it worth investing in mental health promotion and prevention of 
mental disorders? Evidence from economic evaluations.] In: Meggeneder, O. 
Tagungsband zur Wissenschaftlichen Jahrestagung der Österreichischen 
Gesellschaft für Public Health, in print.  
 
non peer-reviewed 
articles 
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Falkner E., Eder C. (2007): Health Technology Assessment: Evaluation of 
Costs and Benefits of Therapies & Methods. ESAO 2007 - XXXIV. Confer-
ence European Society for Artificial Organs, Krems 2007, published in Int. J. 
Artif. Org. 
Falkner E., Eder C., Mathis S., Wild C. (2007): Health Technology Assess-
ment (HTA): Evaluation of Costs and Benefits of Tissue Engineering, BIO-
SPINE 2, 2nd International Congress – Biotechnologies for Spinal Surgery, 
Leipzig 2007, published in European Spine Journal. 
Eder C., Falkner E., Mickel M., Ogon M. (2007): The Chick Chorionallan-
toic Membrane: A Rapid, Cheap and Simple Model for Pre-Assessment of 
Biocompatibility in Tissue Engineering Research. BIOSPINE 2, 2nd Interna-
tional Congress – Biotechnologies for Spinal Surgery, Leipzig 2007, pub-
lished in European Spine Journal. 
Eder C., Bartl R., Meissner J., Mickel M., Falkner E., Ogon M. (2007): Tis-
sue Engineering of the Intervertebral Disk: Does Donor Pathology Matter? 
BIOSPINE 2, 2nd International Congress – Biotechnologies for Spinal Sur-
gery, Leipzig 2007, published in European Spine Journal. 
Falkner E., Eder C., Wild C. (2007): Evaluation of Regenerative Medi-
cine/Tissue Engineering Approaches by Health Technolgy Assessment. 3rd 
World Congress on Regenerative Medicine, Leipzig 2007, published in Re-
generative Medicine. 
Felder-Puig R. (2007): Therapie mit Trastuzumab (Herceptin®). Optimale 
Dosierung und Behandlungsdauer? [Trastuzumab (Herceptin®. Optimal 
dose and duration of treatment?]. Vortragsreihe „HTA in Krankenanstal-
ten”, Wien, 02-27-2007. 
Felder-Puig R. (2007): Das ärztlich-therapeutische Gespräch: Die Effektivi-
tät verstärkter Arzt-Patienten-Kommunikation [The effectiveness of the the-
rapeutic conversation]. Generaldirektion Hauptverband der österr. Sozial-
versicherungsträger, 03-12-2007 
Felder-Puig R. (2007): Das ärztlich-therapeutische Gespräch: Die Effektivi-
tät verstärkter Arzt Patienten-Kommunikation [The effectiveness of the the-
rapeutic conversation]. Gastvortrag am Institut für Kommunikationswissen-
schaft, Universität Salzburg,  Salzburg, 03-12-2007. 
Felder-Puig R., Guba B. (2007): Einsatz von Kyphoplastie und Ver-
tebroplastie bei PatientInnen mit schmerzhaften Wirbelkörperkompressi-
onsfrakturen – eine österreichische Anwendungsbeobachtung [Kyphoplasty 
and vertebroplasty for the treatment of painful vertebral compression fractu-
res.  An Austrian study]. 8. Jahrestagung des Deutschen Netzwerks für evi-
denzbasierte Medizin, Berlin, March 22-24, 2007. 
Felder-Puig R. (2007): Das ärztlich-therapeutische Gespräch: Die Effektivi-
tät verstärkter Arzt Patienten-Kommunikation [The effectiveness of the the-
rapeutic conversation]. Gastvortrag in der Vorstandssitzung des Hauptver-
bands der österreichischen Sozialversicherungsträger. Wien, 04-24-2007. 
Felder-Puig R., Turk E., Guba B., Wild C. (2007): The effectiveness of the 
therapeutic conversation in general practice. HTA for Evidence-Based Pub-
lic Health, Barcelona, June 17-20, 2007. 
Puig S., Felder-Puig R. (2007): Relevanz der diffusionsgewichteten Bildge-
bung für das Outcome nach Schädelhirntrauma – ein systematischer Review 
[Clinical relevance of diffusion-weighted imaging for the outcome after 
contributions at 
conferences 
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brain injury – a systematic review]. 42. Jahrestagung der Deutschen Gesell-
schaft für Neuroradiologie, Frankfurt/Main, Aug 29 –Sept 1, 2007. 
Felder-Puig R. (2007): Akademische klinische Forschung – quo vadis?  
[Barriers to accademic clinical research in Austria]. Gastvortrag an der Uni-
versitätsklinik für Dermatologie, AKH Vienna, 12-12-2007 
Guba B. (2007): The Role of the Information Specialist in the Context of 
Health Technology Assessment. Workshop of the European Association for 
Health Information and Libraries, Krakau, Sept 12-15, 2007. 
Mad P. (2007): Robotik in der Urologie; HTA in Krankenanstalten, Vienna, 
o2-27- 2007. 
Mad P. (2007) Photodynamische Therapie.  Palliation maligner Stenosen im 
Verdauungstrakt, HTA in Krankenanstalten, Vienna, 05-22- 2007. 
Mad P., Guba B., Langer T. (2007): University Outpatient Departments: Ro-
le and positioning in the health care system; A literature review [Rolle und 
Positionierung von Ambulanzen an Universitätskliniken im Gesundheitswe-
sen; eine Literaturübersicht]. 4th HTAi Annual Meeting, Barcelona, Juni 
2007, Poster M-166. 
Radlberger P., Wild C., Guba B. (2007): Breast Cancer Screening Pro-
grammes: Evaluation aside from clinical and economical aspects.     ISPOR 
10th Annual European Congress – Expanding European Horizons for Phar-
macoeconomics and Outcomes Research, Dublin, Okt 20-23, 2007. 
Wild C. (2007): HTA und Evidenzbasierte Versorgungsforschung, 
A3CP/Austrian Competence Circle for Clinical Pathways, Vienna, 01-26-
2007. 
Wild C. (2007): HTA und Qualitätssicherung. Fortbildung bei Kassenärztli-
che Vereinigung Nordrhein, Düsseldorf, 02-03-2007 
Wild C. (2007):  HTA und Evidenzbasierte Versorgungsforschung, 
A3CP/Austrian Competence Circle for Clinical Pathways, Vienna, 02-26-
2007 
Wild C. (2007): Health Technology Assessment – Einsatzgebiete in Öster-
reich. Fortbildung an der 1. Medizinischen Abteilung des Wilhelminenspi-
tals (Zentrum für Hämatologie und Onkologie, Vorstand Univ. Prof. Dr. 
Heinz Ludwig), Wien, 03-08-2007. 
Wild C. (2007): Das LBI für HTA, Ludwig Boltzmann Vorstandssitzung, 
Wien, 03-27-2007. 
Wild C. (2007): Health Technology Assessment, Europäisches Forum Alp-
bach & FOPI/ Forum pharmazeutischer Industrie, Vienna, 03-28-2007. 
Wild C. (2007): Health Technology Assessment in Europe, Roche-
Europatagung, Wien, 03-30-2007. 
Wild C. (2007): Health Technology Assessment in Österreich, Erfahrungen 
und Beispiele, UMIT-PH-course, Hall/Tyrol, 04-17-2007. 
Wild C. (2007): Übertragungsmöglichkeiten von Health in All Policies in 
Österreich. Österreichische Public Health Tagung, Podiumsdiskussion, 
Linz, 09-21-2007. 
Wild C. (2007): Emerging Technologies Newsletter, Jahresversammlung Eu-
roScan und WP7/ EUnetHTA-Treffen, Dublin, April 12-13, 2007. 
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Wild C. (2007): Neonatologische Erstversorgung von Neugeborenen ohne 
vorab bekanntes Komplikationsrisiko. Ansätze einer evidenzbasierten Ver-
sorgungsplanung, Geburtenregister-Fachbeirat, Graz, 05-29-2007. 
Wild C. (2007): EUnetHTA- Emerging Technologies, HTAi preconference 
Workshop, Barcelona, 06-17-2007. 
Wild C. (2007): Fortschritt und Nutzen: Wieviel (marginalen) Nutzen ist 
genug, um noch bezahlt zu werden? Gemeinsame Jahrestagung der Deut-
schen, Österreichischen und Schweizerischen Gesellschaften für Hämatolo-
gie und Onkologie, Basel, 10-09-2007. 
Wild C. (2007): Workshop: Zur Einführung von Health Technology Assess-
ment. 4. Schweizerischer Kongress für Gesundheitsökonomie und Gesund-
heitswissenschaften, Bern, 10-19-2007. 
Wild C. (2007):  Zur Institutionalisierung von Health Technology Assess-
ment: Unabhängigkeit oder gesetzliche Grundlage? 4. Schweizerischer Kon-
gress für Gesundheitsökonomie und Gesundheitswissenschaften, Bern, 10-
19-2007. 
Wild C.  (2007): Verteilungsgerechtigkeit und Ressourcenallokation: Fokus 
Kindermedizin. 1. Jahrestagung Politische Kindermedizin: Werte & Öko-
nomie, Salzburg, Okt 19-20, 2007. 
Wild C. (2007): Ideen/ Möglichkeiten / Grenzen für Support von innovati-
ven Arzneimitteln, public discussion at LISA, VR Life Science Circle, Vien-
na, 10-22-2007. 
Wild C. (2007): Ressourcenallokation, Nutzenbewertung, Nutzen-Schaden 
Relation und Drug-Eluting Stents. Jahrestagung der Österreichischen Ge-
sellschaft für Interventionelle Kardiologie, Linz, 10-30-2007. 
Wild C.  (2007):  Zur Institutionalisierung von ealth Technology Assess-
ment. Österreichische Gesellschaft für Gesundheitsökonomie, Vienna, 11-
14-2007. 
Wild C. (2007): Avastin for AMD / age-related macula degeneration, infor-
mal meeting at BMG, Berlin, 07-12-2007 
Zechmeister I. (2007): Die Finanzierung der Psychiatrie in Europa im 
Wandel. Überblick und Aussichten [Mental Health Care Financing in 
Europe. Overview and Trends]. Workshop ‚DRGs in der Somatik. Folgen 
für die Psychiatrie?’, Berlin, Jan 25-27, 2007 
Zechmeister I. (2007):  Is it worth investing in mental health promotion and 
prevention of mental disorders? A review of the evidence on economic 
evaluations. 8th workshop on costs and assessment of psychiatry: ‘Investing 
in Mental Health Policy and Economics Research’, Venice, March 09-11, 
2007. 
Zechmeister I. (2007):  Adaption eines Markov Modells zur Simulation einer 
‚Real-life Kohorte’ für Statintherapie in Österreich: Diskussion zu Methode 
und Datenauswahl. [Adapting a Mardov Model for the simulation of a ‚real-
life cohort’ of statin users in Austria: Discussion of method and data 
sources.] 8. Jahrestagung des DNEbM, Berlin, March 22-24, 2007 (Poster). 
Zechmeister I. (2007): Gebärmutterhalskrebsprävention: Ist die HPV Imp-
fung kosteneffektiv? [HPV vaccination for the prevention of cervical carci-
noma: Is it cost-effective?] HTA in Krankenanstalten, Vienna, 05-22-2007. 
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Zechmeister I. (2007): Is it worth investing in mental health promotion and 
prevention of mental disorders? A review of the evidence from economic 
evaluations. Health Technology Assessment international Conference, Bar-
celona, June 18-20, 2007. 
Zechmeister I.  (2007): Is it worth investing in mental health promotion and 
prevention of mental disorders? A review of the evidence from economic 
evaluations. International Health Economics Association Conference, Co-
penhagen, July 09 -11, 2007. 
Breyer E. (2007): Nanotechnologie in der Medizin: Hoffnung und Risiken 
[Nanotechnologies in medicine: hopes and risks]. HTA-Newsletter Septem-
ber 2007, Nr. 60. 
Breyer E. (2007): Heimdialyse: Patientencharakteristika [Patient characte-
ristics for home dialysis]. HTA-Newsletter Oktober 2007, Nr. 61. 
Breyer E., Adelbrecht Ch. & Wild C. (2007): Avastin® bei altersbedingter 
Makuladegeneration [Avastin® for age-related macular degeneration]. 
HTA-Newsletter Oktober 2007, Nr. 61. 
Breyer E. (2007): Magnetfelder: Sanfte Medizin oder Umweltgefahr [Magne-
tic fields]. HTA-Newsletter November 2007, Nr. 62. 
Falkner E. (2007): Tissue Engineering: Züchtung von Gewebe [Tissue Engi-
neering]. HTA-Newsletter May 2007, Nr. 57 
Falkner E., Wild C. (2007): Cell Salvage. Fremdblut sparende Maßnahmen 
[Cell salvage for minimising perioperative allogeneic blood transfers]. HTA-
Newsletter July/August 2007, Nr. 59. 
Falkner E. (2007): Zentralvenöse Portsysteme. Risikofaktor Thrombosen 
[Central venous port system associated thromboses]. HTA-Newsletter No-
vember/Dezember 2007, Nr. 62. 
Falkner E. (2007): Thromboseprophylaxe bei operativen Eingriffen [Reduc-
ing the risk of venous thromboembolism]. HTA-Newsletter Novem-
ber/Dezember 2007, Nr. 62. 
Felder-Puig R. (2007): Altersbedingte Makuladegeneration. Therapie & Le-
bensqualität [Age-related macular degeneration. Treatment and quality of 
life]. HTA-Newsletter  January 2007, Nr. 53. 
Felder-Puig R. (2007): Gewichtsreduktion bei Bluthochdruck. Behandlungs-
strategien [Hypertension and weight-loss. Treatment options]. HTA-
Newsletter  February 2007, Nr. 54. 
Felder-Puig R. (2007): Rückenschmerzen. Zahlreiche Verfahren [Back pain. 
Numerous interventions]. HTA-Newsletter  March 2007, Nr. 55. 
Felder-Puig R. (2007): Diskusprothesen. Neue Studienergebnisse [Artificial 
cervical discs. Recent study results]. HTA-Newsletter  May 2007, Nr. 57. 
Felder-Puig R. (2007): Interventionen bei Demenz-Kranken. Prävention von 
rastlosem Herumwandern [Non-pharmacological interventions to prevent 
wandering in dementia]. HTA-Newsletter  July/August 2007, Nr. 59. 
Felder-Puig R. (2007): Ganzkörper-CT Screening. Mehr Schaden als Nut-
zen? [Whole-body-CT screening. More harm than benefit?]. HTA-
Newsletter September 2007, Nr. 60. 
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Geiger-Gritsch S. (2007): Avastin® (Bevacizumab). „Off-Label-Use” bei 
Krebs [Avastin® (Bevacizumab). „Off-Label-Use” in cancer]. HTA-
Newsletter  June 2007, Nr. 58. 
Mad P. (2007): Drug Eluting Stents. Sicherheit von DES. HTA-Newsletter  
January 2007, Nr. 53. 
Mad P. (2007): Robotik in der Urologie. Eingriffe an der Prostata. HTA-
Newsletter  February 2007, Nr. 54. 
Mad P. (2007):  Glaukom: Screening-Verfahren auf dem Prüfstand. HTA-
Newsletter March 2007, Nr. 55. 
Mad P. (2007): Telemonitoring bei chronischer Herzinsuffizienz. HTA-
Newsletter April 2007, Nr. 56. 
Mad P. (2007):  Photodynamische Therapie: Palliation maligner Stenosen 
im Verdauungstrakt. HTA-Newsletter June 2007, Nr. 58. 
Mad P. (2007):  Versorgungs-Forschung: Effektivität qualitätsfördernder 
Maßnahmen. HTA-Newsletter September 2007, Nr. 60. 
Mathis S. (2007): Interstitielle Brachytherapie. HTA-Newsletter May 2007, 
Nr. 57 
Radlberger P. (2007): P450-Genotypisierung. Mangelnde Evidenz für Geno-
typisierungen. HTA-Newsletter January 2007, Nr. 53 
Radlberger P. (2007): Früherkennungsprogramme. Unterschiedliche Ein-
flussfaktoren auf die Partizipationsrate bei Screenings. HTA-Newsletter 
March 2007, Nr. 55. 
Radlberger P. (2007): P450-Genotypisierung. Mangelnde Evidenz für Geno-
typisierungen. HTA-Newsletter January 2007, Nr. 53. 
Radlberger P. (2007): Früherkennungsprogramme. Unterschiedliche Ein-
flussfaktoren auf die Partizipationsrate bei Screenings. HTA-Newsletter 
March 2007, Nr. 55. 
Radlberger P. (2007): Wundversorgung: Vakuumversiegelung.  HTA-News-
letter April 2007, Nr. 56. 
Radlberger P. (2007): Massenspektrometrie: Früherkennung von Stoffwech-
selerkrankungen bei Neugeborenen. HTA-Newsletter September 2007, Nr. 
60. 
Radlberger P. (2007): Epilepsie: medikamentöse Behandlung. HTA-News-
letter November 2007, Nr. 62. 
Wild C. (2007): Wachstumshormone. HTA-Newsletter February 2007, Nr. 
54. 
Wild C. (2007):  Biosimilars. HTA-Newsletter February 2007, Nr. 54. 
Wild C., Zechmeister I. (2007): Ressourcenallokation und Verteilungsge-
rechtigkeit. Rationierungsethiken. HTA-Newsletter July 2007, Nr. 59. 
Zechmeister I. (2007): Altersbedingte Makuladegeneration. Diagnostik der 
AMD. HTA-Newsletter April 2007, Nr. 56. 
Zechmeister I. (2007): Hepatitis C Behandlung. HTA-Newsletter July 2007, 
Nr. 59. 
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Wild C., Zechmeister I. (2007): Ressourcenallokation und Verteilungsge-
rechtigkeit. Rationierungsethiken. HTA-Newsletter July 2007, Nr. 59. 
Zechmeister I. (2007):  Sozialpolitische Maßnahmen bei psychischen Er-
krankungen. HTA-Newsletter September 2007, Nr. 60. 
2.3 Participation in Scientific Meetings & 
Conferences 
8th Conference on Cost and Assessment in Psychiatry: ‘Investing in Mental 
Health Policy and Economics Research’, Venice, March 09-11, 2007 (Ingrid 
Zechmeister) 
8th Annual Meeting of the German Network of Evidence-based Medicine, 
Berlin, March 22-24, 2007 (Rosemarie Felder-Puig, Beate Guba, Claudia 
Wild, Ingrid Zechmeister) 
Symposium „Korrupt oder korrekt: Wie bleibt die Selbsthilfe unabhängig?”, 
Berlin,  04-27-2007  (Beate Guba)  
TA07 „Technikfolgenabschätzung zwischen Inter- und Transdisziplinari-
tät”, Vienna, 06-04-2007 (Claudia Wild, Ingrid Zechmeister) 
4th Annual Meeting of HTAi: HTA for Evidence-Based Public Health, Barce-
lona ,June 17-20, 2007 (Rosemarie Felder-Puig, Beate Guba, Philipp Mad, 
Philipp Radlberger, Stefan Mathis, Claudia Wild, Ingrid Zechmeister) 
DG SANCO & BMGFJ (ÖBIG): Pharmaceutical Pricing and Reimburse-
ment Information PPRI, Vienna, 06-29-2007, (Claudia Wild, Philipp Radl-
berger) 
6th Biennial World Congress der „International Health Economics Associa-
tion”, Copenhagen, July 09-11, 2007 (Ingrid Zechmeister) 
ESAQ 2007 – XXXIV. Conference European Society for Artificial Organs, 
Krems, Sept 5-8, 2007 (Erwin Falkner) 
EAAT Conference 2007 – Annual Meeting of the European Association of 
Addiction Therapy, Vienna, Sept 10-12, 2007 (Philipp Radlberger) 
Workshop of the European Association for Health Information and Librar-
ies, Krakau, Sept 12-15, 2007 (Beate Guba) 
GMDS-Tagung „Medizin und Gesellschaft”, Augsburg, Sept 17-21, 2007 
(Sabine Geiger-Gritsch, Beate Guba) 
BIOSPINE 2, 2nd International Congress – Biotechnologies for Spinal Sur-
gery, Leipzig, Sept 19-20, 2007 (Erwin Falkner) 
10th annual conference of the Austrian Society for Public Health, Linz, Sept 
20-21, 2007 (Claudia Wild, Ingrid Zechmeister, Gerald Gartlehner, Philipp 
Radlberger) 
15th European Conference on Public Health – The Future of Public Health 
in the Unified Europe, Helsinki, Oct 11-13, 2007 (Stefan Mathis) 
3th World Congress on Regenerative Medicine, Leipzig, Oct 18-20, 2007 (Er-
win Falkner)  
conferences 
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8. HTA-Symposium von DAHTA@DIMDI: Entscheiden in der Medizin,  
Köln, Oct 18-19, 2007 (Sabine Geiger-Gritsch) 
ISPOR 10th Annual European Congress – Expanding European Horizons for 
Pharmacoeconomics and Outcomes Research, Oct 20-23, 2007, Dublin (Ge-
rald Gartlehner, Sabine Geiger-Gritsch, Philipp Radlberger, Ingrid Zech-
meister) 
HTA-conference 2007, London, 11-01-2007 (Claudia Wild) 
Risk Governance of Nanotechnologies: The International State-of-the-Art, 
Vienna, 09-25-2007 (Stefan Mathis) 
Haemovigilance and tissue vigilance. Institute for International Research 
(I.I.R.), Vienna, Oct 9-10, 2007 (Erwin Falkner) 
Role of effector molecules of natural born defence in burns, seminar at LBI 
for experimental and clinical traumatology / clusters for tissue regeneration, 
Vienna 10-25-2007 (Erwin Falkner) 
Cartilage Regeneration – Where are we at? Seminar LBI for experimental 
and clinical traumatology / clusters for tissue regeneration, Vienna, 11-09-
2007 (Erwin Falkner) 
WISSENnetworx Workshop „Wissen was läuft: Semantische Technologien 
im Wissensmanagement”, Salzburg, 11-15-2007 (Beate Guba). 
Biosimilars – Neue Herausforderungen für das Gesundheitssystem, Vienna, 
11-26-2007  (Stefan Mathis) 
EUnetHTA WP4 project-coordination meeting, Helsinki, Jan 18-19, 2007 
(Philipp Radlberger) 
EUnetHTA WP5 project-coordination meeting, Venice, Sept 27-28, 2007 
(Philipp Radlberger) 
 
seminars, lectures 
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3 Scientific Co-operations 
INAHTA annual meeting, Barcelona, June 20-22, 2007 (Claudia Wild)  
INAHTA and HTAi Workshop on Ethical Issues, Oslo, Sept 21-23, 2007 
(Stefan Mathis) 
EUnetHTA WP4 project coordination meeting, Helsinki, Jan 27-28, 2007 
(Philipp Radlberger) 
EUnetHTA WP1 Executive Meeting, Barcelona, 03-22-2007 (Claudia Wild) 
EUnetHTA WP7 project coordination meeting, Dublin, April 11-14, 2007 
(Claudia Wild, Rosemarie Felder) 
EUnetHTA WP5 project coordination meeting, Venice, Sept 27-28, 2007 
(Philipp Radlberger) 
EUnetHTA WP1 executive meeting, Stockholm, Oct 11-12, 2007 (Claudia 
Wild) 
4th Meeting of the EUPHORIC Project, Helsinki, 10-09-2007 (Stefan Mathis) 
InnoHTA, kick-off-meeting, Brussels, 01-26-2007 (Philipp Radlberger) 
InnoHTA, project coordination meeting, Vienna, May 2-3, 2007 (Claudia 
Wild, Sabine Geiger-Gritsch, Philipp Radlberger) 
InnoHTA, project coordination meeting, Lübeck, Dec 12-14, 2007 (Philipp 
Radlberger) 
MHEEN (Mental Health Economics European Network) meeting, Ljubl-
jana, June 28-30, 2007 (Ingrid Zechmeister) 
Cooperation with ScHARR (School of Health and Related Research) at Shef-
field University/UK on Devoloping a decision analytic model for statin 
therapy in Austria (Ingrid Zechmeister) 
Cooperation with the Institute for Microparasite Epidemiology/Imperial 
College London/UK, the Institute for Medical Science/Department of Bio-
statatistics/University of Oslo/Norway and with the Norwegian Knowledge 
Centre fort he Health Service on Adaptation of a health economic analysis 
for the evaluation of HPV-vaccination in Austria (Ingrid Zechmeister) 
Dialog<>Gentechnik-collaboration in working group on genetic data, Vi-
enna, 10-04-2007 (Stefan Mathis) 
INRO / International Neurotrauma Research Organization – cooperative 
project for optimizing first aid in craniocerebral injury patients, Vienna, 11-
09-2007 (Claudia Wild) 
Registry workshop with EFORT coordinator, Orthopaedic University clinic, 
Innsbruck, 11-29-2007 (Stefan Mathis) 
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The following authors contributed articles to the HTA newsletter:  
b Dr. Christopher Adlbrecht, AKH Wien 
b Univ.-Prof. Dr. Reinhard Busse, Institut für Management im Gesund-
heitswesen an der TU-Berlin 
b Mag. Andrea Fried, ÖKZ/ Österreichische Krankenhauszeitung 
b Mag. Sylvia Groth,  MAS, Frauengesundheitszentrum Graz 
b DDr. Andrea Korencan 
b Dr. Gerold Labek, EFORT Arthroplasty Register Coordinator, Orthopä-
dische Universitätsklinik Innsbruck 
b Dipl.-Soz. Thomas Langer, ÄZQ Berlin 
b MMag. Sigrid Metz, Nationales Referenzzentrum für nosokomiale Infek-
tionen und Antibiotikaresistenz, A.ö. Krankenhaus der Elisabethinen 
Linz 
b Univ.-Prof. Dr. Helmut Mittermayer, Nationales Referenzzentrum für 
nosokomiale Infektionen und Antibiotikaresistenz, A.ö. Krankenhaus der 
Elisabethinen Linz 
b Dr. Heide Said, MPH, Österreichische Gesellschaft für Public Health 
b Dr. Marcial Velasco-Garrido, Institut für Management im Gesundheits-
wesen an der TU-Berlin 
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4 Other Activities  
Claudia Wild teaches ‚Health Technology Assessment’ for the Master’s 
Course for Public Health at the Medical University of Graz & at Master’s 
Course for „Public Health Hospital Management” at the Institute of Eco-
nomics in Linz. She is lecturer for the postgraduate course Master of Man-
agement in Health Care at the Danube University Krems. 
Claudia Wild taught „Ethics in resource allocation in health care” at the In-
stitute for Philosophy at the University of Vienna (winter semester 2007).  
Ingrid Zechmeister teaches ‚Economic evaluation in health care’ for the 
Masters Course for Public Health at the Medical University of Graz. 
Beate Guba held two workshops on „Searching the Internet” at the Austrian 
health ministry. 
Gerald Gartlehner is an Adjunct Assistant Professor for Public Health at the 
University of North Carolina at Chapel, School of Public Health. 
Claudia Wild carries out review activities for the journals ‚Healthcare Pol-
icy’, „Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswe-
sen”, ‚European Journal for Public Health’ und ‚Healthcare Policy—
Politiques de Santé’. Also, she participated in the project „quality in health-
care systems with emphasis on health policy options for Austria” in coopera-
tion with the London School of Economics, where she is a member of the re-
search board. 
Moreover she joined the working group Public Health at Transparency In-
ernational – Austrian Chapter and consulted the Court of Auditors in Upper 
Austria. 
Ingrid Zechmeister was editor of the 2/2007 issue of the journal ‚Kurs-
wechsel’. Furthermore, she carried out review activities for the Journal „So-
cial Science and Medicine” and for developing research quality criteria for 
publications by the Upper Austrian health insurance fund.  
In 2007 Beate Guba carried out review activities for the „Verein zur 
Förderung der Informationswissenschaft”. 
In 2007  Gerald Gartlehner reviewed manuscripts for the following peer-
reviewed journals: Drug Safety, Archives of Internal Medicine, Seminars in 
Arthritis and Rheumatism, International Journal of Quality in Healthcare, 
and Quality of Life Research 
The following diploma and doctoral theses were supervised by Claudia Wild 
and supported by services of the library of the LBI-HTA: 
b Marc Krenn (Alpen-Adria-Universität Klagenfurt): Telemonitoring for 
cardiovascular diseases (working title) 
b Mag. Elisabeth Breyer (IMC Krems): Applications of new medical inter-
ventions of solidary health care systems (working title) 
b Mag. Petra Petz (University of Vienna): Recombinant growth hormone 
(working title) 
b Mag. Martina Nitsch (University of Vienna): Agenda setting in medical 
journalism (working title) 
teaching  
expert &  
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Because the LBI-HTA intends to enable long-term and free access to its pub-
lications, emphasis has been placed on the development of a document 
server. The server provides extensive search options in English and German. 
In addition to this channel of distribution which is important for the trans-
fer of knowledge the delivery of publications to the Library of the Medical 
University of Vienna and the legal deposit of copies ensure that scientists 
and students in Austria become familiar with the Institute’s publications. In 
order to raise awareness of the Institute’s research results internationally, 
summaries and other relevant information are regularly sent to the INAHTA 
office. Due to this cooperation, project reports and rapid assessments from 
the LBI-HTA have also been accepted into the HTA-Database of the Centre 
for Reviews and Dissemination in York, and are accessible via 
http://www.crd.york.ac.uk/crdweb/. 
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5 Prospects  
In 2008 there are diverse challenges:  
Firstly, organizational growth is an issue. The new partnership with the 
HVB as well as further third party projects and rapid policy advising (re-
ports) need to be processed while maintaining high standards of research. 
Secondly, methods developed in 2007 will be used to evaluate individual 
medical services for the DRG catalogue for the federal ministry of health be-
tween January and March. The whole research team is involved in the task. 
Thirdly, as a consequence of cooperation with the Donauuniversität Krems, 
there will be a six day HTA course taking place in Krems. Due to high de-
mand, the course will be held twice in 2008. 
After the foundation of the „LBI für Gesundheitsförderungsforschung” (the 
former LBI for medical sociology, LBI-HTA) clustering and close coopera-
tions are planned. Also to the already established partnership with the 
UMIT a new cooperation will be added namely with the newly founded in-
stitute for evidence based medicine at the Donauuniversität Krems. The 
head of that institute will be Dr. Gerald Gartlehner – member of the LBI-
HTA at the time being.  
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